Anomalies of imagination—disturbances in the basic structure of fantasies and imagery—are highly characteristic of schizophrenia-spectrum disorders and closely related to self-disorders. In a study of 81 participants, including patients with schizophrenia or other non-affective psychosis, schizotypal personality disorder, other mental illness, and healthy controls, these anomalies aggregated significantly in the schizophrenia-spectrum group compared to other mental illness and healthy controls, with no difference between schizophrenia and schizotypal disorder. Network analysis showed anomalies of imagination were closely interconnected with self-disorders, while correlations with perceptual disturbances and positive, negative, and general symptoms were moderate but separated in the network.
A systematic review of psilocybin for eating disorders found only two original studies meeting inclusion criteria: an open-label feasibility study with 10 individuals with anorexia nervosa and a single case report. Six registered clinical trials were also identified. The initial evidence suggests psilocybin may be safe and well-tolerated in anorexia nervosa, but the authors emphasize the need for larger samples. The review highlights the lack of approved pharmacological treatments for eating disorders beyond fluoxetine for bulimia nervosa and calls for further research.